How cannabis affects brain immunity: What science reveals so far

This review examines how over 120 naturally occurring phytocannabinoids and 190 synthetic cannabinoids affect two critical brain cell types: microglia and astrocytes. These cells are the brain's immune responders and key regulators of neuroinflammation—a damaging inflammatory process linked to neurodegenerative diseases like Parkinson's and Alzheimer's. The research team systematically analyzed evidence across major scientific databases to understand how cannabinoids interact with CB2 receptors on these brain cells, which is particularly important given the rising recreational and illicit use of cannabinoid products worldwide.

The findings reveal a critical distinction based on exposure patterns: acute (short-term) cannabinoid exposure appears neuroprotective, potentially reducing harmful inflammation. However, chronic (long-term) effects remain unclear and require further study. Notably, Δ9-tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis, may actually promote glial cell activation and promote neuroinflammation—the opposite of the protective effect. Interestingly, some synthetic and semi-synthetic cannabinoids appear to retain protective properties, suggesting that cannabinoid structure matters significantly for health outcomes.

These findings have important implications for cannabis users, highlighting that long-term safety profiles are not yet established and that different cannabinoid compounds may have very different effects on brain health. The researchers emphasize the urgent need for well-designed longitudinal studies and in vivo research to determine whether cannabinoids could serve as therapeutic tools for neurodegenerative diseases while informing regulatory policies that protect public health.